Mumbai: A study conducted by Tata Memorial Hospital in Mumbai has shown that adding Nimotuzumabto the standard treatment regimen significantly improves the 10-year overall survival rate for patients with locally advanced squamous cell carcinoma of the head and neck. Patients with head and neck cancer who received Nimotuzumab in combination with concurrent radiotherapy and cisplatin had a 10-year overall survival …
Branded formulations company Eris Lifesciences Ltd will acquire the domestic branded formulation business of Biocon Biologics Ltd, the biosimilar arm of Biocon, for ₹1,242 crore, the two companies said on Thursday. “This strategic collaboration with Eris Lifesciences for our portfolio of metabolics, oncology, and critical care products in India aligns with our commercial strategy to maximize patient reach and market …
Eris Lifesciences on Tuesday announced the acquisition of the trademark for anti-diabetes novel drug Zomelis for $13 million, the company said in a release. Zomelis, the common name for which is vildagliptin, is used to treat type 2 diabetes, and is the first innovator pharmaceutical product trademark acquisition by Eris Lifesciences. Our inorganic growth strategy continues as we explore good …
